Precigen announces positive phase 1 data for off-the-shelf prgn-2009 adenoverse™ immunotherapy alone and in combination with an investigational checkpoint inhibitor in patients with recurrent/metastatic hpv-associated cancers

–  prgn-2009 combined with an investigational checkpoint inhibitor resulted in a 30% orr in patients with heavily pre-treated hpv-associated cancers that were naÏve or resistant to checkpoint blockade with prolonged duration of responses – –  recurrent/metastatic hpv-associated cancers (cervical, anal, oropharyngeal, etc.) are incurable by current therapies – –  prgn-2009 was safe and well-tolerated with only grade 1 or 2 treatment related adverse events – –  prgn-2009 treatment induced hpv-specific t-cell immune responses and subsequently enhanced t-cell responses with repeat administrations without the development of neutralizing antibodies in the majority of patients – germantown, md.
PGEN Ratings Summary
PGEN Quant Ranking